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Abstract
Background: One of the most important aspects of designing a clinical trial is selecting appropriate outcomes. Patient-
reported outcomes (PROs) can provide a personal assessment of the burden and impact of a malignant disease and its
treatment. PROs comprise a wide range of outcomes including basic clinical symptom scores and complex metrics such
as health-related quality of life (HRQoL). There is limited data on how postoperative complications following cancer
surgery affect symptoms and HRQoL. For this reason the primary aim of the PATRONUS study is to investigate how
perioperative complications affect cancer-related symptoms and HRQoL in patients undergoing abdominal cancer
surgery. The PATRONUS study is designed and will be initiated and conducted by medical students under the direct
supervision of clinician scientists based on the concept of inquiry-based learning.
Methods: PATRONUS is a non-interventional prospective multicentre cohort study. Patients undergoing elective
oncological abdominal surgery will be recruited at regional centres of the clinical network of the German Surgical Society
(CHIR-Net) and associated hospitals.
A core set of 12 cancer associated symptoms will be assessed via the PRO version of the Common Terminology Criteria
for Adverse Events. The cancer-specific HRQoL will be measured via the computerised adaptive testing version of the
European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30. PROs will be measured eight times over
a period of six months. The short-term clinical outcome measure is the rate of postoperative complications (grade II to V)
within 30 days according to the Clavien-Dindo classification. The long-term clinical outcome is overall survival within six
months postoperative.
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Discussion: PATRONUS will provide essential insights into the patients’ assessment of their well-being and quality of life
in direct relation to clinical outcome parameters following abdominal cancer surgery. Furthermore, PATRONUS will
investigate the feasibility of multicentre student-led clinical research.
Trial registration: German Clinical Trials Register: DRKS00013035 (registered on October 26, 2017).
Universal Trial Number (UTN): U1111–1202-8863.
Keywords: Patient-reported outcome measures, Quality of life, Neoplasms, Postoperative complications, General surgery,
Digestive system surgical procedures, CHIR-Net, SIGMA
Background
Cancer is the second most common cause of death in
Germany following cardiovascular diseases [1]. Due to
demographic changes, the incidence and prevalence of ma-
lignancies in Germany will rise sharply within the next years
[2–4]. According to German national data, the most fre-
quent lethal tumour diseases include solid neoplasms of the
abdominal cavity including pancreatic, liver, gastric and
colorectal cancers [5]. For these tumours, surgery is the
mainstay of curative as well as palliative treatment. At the
same time, cancer patients will become older and comorbid
[2, 6, 7]. Therefore patients, caregivers and specialists will
face new challenges in the care of cancer patients. Accord-
ingly the design and focus of clinical trials will need to adapt
to this changing environment with an increasing need to in-
tegrate the patients’ perspective in clinical studies.
For this purpose, patient-reported outcomes (PROs)
have been introduced next to survival and morbidity
endpoints in oncological trials. PROs can be defined as
‘any outcome evaluated directly by the patient himself or
herself and is based on the patient’s perception of a dis-
ease and its treatment(s)’ [8] and are measured via vali-
dated PRO measures (PROMs). PROMs in oncological
trials can be classified into two main groups: PROMs for
the assessment of cancer- and treatment-related symp-
toms and PROMs to measure health-related quality of
life (HRQoL) [9]. Recently, two new PROMs have been
proposed for each purpose: the EORTC has evaluated a
digital, computer adaptive testing (CAT) version of their
widely used cancer-specific HRQoL questionnaire C30
(CAT EORTC QLQ-C30) [10–12] and the National Can-
cer Institute (NCI) has validated a PROM version of the
Common Terminology Criteria for Adverse Events
(PRO-CTCAE) to measure cancer or treatment associ-
ated symptoms [13]. In addition, the NCI has defined a
core-set of 12 symptoms that should be reported in all
cancer trials [14].
PROs can provide additional benefit in clinical trials as
they might provide a personal assessment of the burden of
a malignant disease and its treatment and might comple-
ment survival, morbidity and safety data, thus enabling a
full risk-benefit assessment [8]. Although PROs have been
applied frequently in cancer trials, astonishingly little is
known about the relationship between clinical endpoints
and the well-being of cancer patients undergoing abdom-
inal surgery. Arguably the most important clinical out-
come in surgical oncology from a patient’s point of view
is, apart from survival, the frequency and severity of com-
plications. To this end the Clavien-Dindo classification
which grades postoperative complications according to
their sequelae has gained wide acceptance [15, 16]. Al-
though it seems intuitive that complications adversely
affect HRQoL and symptoms, the extent to which HRQoL
and symptoms are affected is unknown. It is therefore also
unclear whether complications considered more severe in
the Clavien-Dindo classification system [15, 16], i.e. those
with a higher severity grade, are related to reduced
HRQoL or symptoms. Although several cross-sectional
studies have evaluated HRQoL in patients who had under-
gone oncological abdominal surgery and found an associ-
ation between postoperative complications and decreased
long-term HRQoL [17–19], these results are questionable
considering the design of these studies and their insuffi-
cient validity [20]. Most of the few available prospective
trials have been performed exclusively in colorectal cancer
surgery and show heterogeneous results, with some dem-
onstrating no [21], some short-term [22] and some also
long-term effects of complications on certain subdomains
of HRQoL [23, 24]. For other cancers of the gastrointes-
tinal tract, including pancreatic [25] and oesophageal can-
cer [26], data are even more sparse. Furthermore, the
majority of these studies exhibit severe methodological
limitations including single-centre design, limited number
of patients, inadequate follow-up, and high rate of missing
data. Finally, all of these studies used a wide range of dif-
ferent PROMs and frequently no standardised morbidity
assessment. Therefore, a prospective multicentre study
using validated complication measurements and PROMs
seems urgently warranted.
Student-led clinical research and learning-by-research
Although the principles of evidence-based medicine (EbM)
are taught in most medical schools, the focus of most EbM
curricula is on the application of EbM-principles in every-
day clinical practice, but not on teaching scientific method-
ology or performing scientific work, i.e. generating new
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scientific evidence. Consequently, a future deficit in aca-
demic faculty seems likely in European countries [27–29].
Inquiry-based learning or learning-by-research are
concepts that refer to a trend in higher education: to
provide students with the opportunity to gain knowledge
by conducting their own scientific inquiries or investiga-
tions. Although the underlying mechanisms still have to
be revealed, projects to provide such research experi-
ences are emerging and show that medical students can
improve their clinical capabilities by contributing to
student-initiated clinical trials [30–32]. Recently, a
student-led initiative has successfully performed a num-
ber of large observational studies in a national cohort
following gastrointestinal surgery demonstrating the
feasibility of this concept [33, 34]. On an even larger
scale the EuroSurg collaborative demonstrated the feasi-
bility of this concept across 20 European countries [35].
However, all of these studies were confined to specific
subpopulations of patients, excluded PROMs and inves-
tigated specific rather than all postoperative complica-
tions. The study idea for the PATRONUS study was
conceived by the Study network of the German Surgical
Society (CHIR-Net; www.chir-net.de). CHIR-Net has suc-
ceeded in creating a German-wide research infrastructure
comprising university and non-university centres. Since its
foundation in 2006, CHIR-Net has recruited more than
11,800 patients in randomised-controlled surgical trials
and consists of 16 regional centres and their associated
partner hospitals [36]. CHIR-Net has recently created a
student-led clinical trial network (Student-initiated
German Medical Audit, SIGMA; www.sigma.university)
[37] which will run the PATRONUS study.
Methods/design
This study protocol is written according to current
SPIRIT guidelines [38]. The SPIRIT checklist is attached
as Additional file 1.
Study design
PATRONUS is a prospective multicentre single-arm ob-
servational cohort study across Germany.
Outcome measures
Patient-reported outcome measures (PROMs)
a) a core set of 12 cancer associated symptoms [14]
(fatigue, insomnia, pain, anorexia, dyspnoea,
cognitive problems, anxiety, nausea, depression,
neuropathy, constipation, diarrhoea) measured via
the PRO-CTCAE [13].
b) cancer-specific HRQoL measured via the CAT
EORTC QLQ-C30 [39, 40].
Clinical outcome measures
a) Short-term clinical outcome measure is the rate of
postoperative complications grade II (minor) and
III-V (major) within 30 days according to the
Clavien-Dindo classification [15].
b) Long-term clinical outcome is overall survival
within 6 months postoperative.
Objectives
The primary aim of the study is to evaluate associations
between the clinical outcomes and the two PROMs in
the short-term (within 30 days) and long-term (after 3
and 6 months) in order to find out whether and to what
extend complications (none/grade I vs. minor (grade II)
vs. major (grade III-V)) influence the two PROMS in 5
predefined surgical cancer subgroups (upper-GI, pancre-
atic, hepatobiliary, colorectal, other abdominal cancers).
Further objectives are:
1. To describe the absolute values of a.) the newly
defined CAT EORTC QLQ-C30 and b.) the set of
12 cancer-specific symptoms [14] measured via the
PRO-CTCAE [13] for oncologic patients undergo-
ing surgery at predefined times from baseline
(preoperative) until 6 months postoperative in the
5 surgical cancer subgroups outlined above.
2. Although both of the proposed PROMs (PRO-
CTCAE [13] and CAT version of the EORTC QLQ-
C30) used in this trial have been validated, they are
new and have never been tested head-to-head.
Therefore, the existence of possible overlapping do-
mains in both PROMs will be analysed.
3. In order to find out if a student-led multicentre ob-
servational study using an electronic data capture
system is feasible.
For the primary objective and further objective 1. and
2., the two PROMs (PRO-CTCAE and CAT version of
the EORTC QLQ-C30) in the short-term (within 30 days)
and long-term (after 3 and 6 months), as well as is the
rate of postoperative complications grade II (minor) and
III-V (major) within 30 days according to the
Clavien-Dindo classification and the overall survival
within 6 months postoperative will be assessed.
For further objective 3 the following endpoints will be
assessed:
a.) Rate of missing PRO data at 3 and 6 months
b.) Rate of missing clinical data at 30 days
c.) Number of participating trial sites including
patients compared to initiated trial sites
d.) Rate of included patients in comparison to screened
patients
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Further endpoints can be found in the description of
the study visits.
Study duration and schedule
The duration of the study for each patient is 6 months
including follow-up. Milestones are listed in Table 1.
The duration of the overall study is expected to be
18 months. Figure 1 displays the patient flow during
the study.
Study conduct and study centres
To enrol an adequate number of patients in the planned
recruitment period, 30 hospitals including regional cen-
tres of the clinical trial network CHIR-Net (www.chir-
net.de/regionalzentren-karte) as well as associated
partner-hospitals will participate in the study.
A CHIR-Net SIGMA steering group for the
PATRONUS study has been set up consisting of the au-
thors of this publication and include the CHIR-Net co-
ordination centre. This steering group has designed the
study and is responsible for trial infrastructure, acquisi-
tion of centres, qualification of participating medical stu-
dents and communication with centres and the public
via digital tools (www.slack.com) and social media
(www.facebook.com/sigmastudynetwork; https://twitter.
com/sigmastudies).
At each trial site a so-called “mini-team” will be estab-
lished consisting of an experienced clinical trialist (sur-
geon) and a group of at least two medical students.
Furthermore, at each site a “local lead” will be appointed.
The local lead is a medical student responsible for creat-
ing the mini-team, recruiting other students to the pro-
ject, interacting with local surgeons and conducting the
study. The local lead in conjunction with the associated
surgeon is also responsible for gaining approval for the
study from his/her local independent ethics committee
according to the German Medical Association’s profes-
sional code (Berufsordnung der Bundesärztekammer).
All student participants will be trained prior to study
initiation. To this end CHIR-Net SIGMA has developed
an in-person and online clinical trials training programme
(SIGMA clinical trial curriculum; SIGMA-CTC) which
will be reported elsewhere.
Interventions
No experimental or control intervention is tested as this
is an observational, non-interventional prospective co-
hort study.
Eligibility criteria
Every local team will recruit patients for the study inde-
pendently. Inclusion criteria are: a.) patient’s age ≥ 18 years;
b.) patient scheduled for elective abdominal surgery for
confirmed or suspected malignancy; c.) patient’s ability to
understand character of the study; d.) planned laparoscopic
or open surgery or any variant (i.e. laparoscopic-assisted,
laparoscopic-thoracoscopic), e.) written informed consent.
Exclusion criteria are a.) language barrier that impedes
follow-up or informed consent, b.) American Society of An-
esthesiologists (ASA) grade ≥ 4.
All patients planned for an elective surgery for sus-
pected or confirmed malignancy are asked for their par-
ticipation in the trial if all inclusion criteria and none of
the exclusion criteria are fulfilled. Screening lists are
kept in order to analyse reasons for non-inclusion of pa-
tients and to calculate the case ascertainment rate.
Patient timelines and description of study visits
Patients will be screened preoperatively (visit 1) by a
member of the mini-team. Patients will be enrolled if
they fulfil the inclusion/exclusion criteria and after hav-
ing given their written informed consent after detailed
patient information. Informed consent is sought by a
member of the mini-team, i.e. medical student or clinical
trialist (surgeon). Baseline data and the first set of
PROMs are collected during screening/baseline visit.
Surgical data is collected during visit 2. Short-term clin-
ical outcome parameters and PROMs are collected dur-
ing visits 3–6 within 30 postoperative days or until
discharge. Long-term clinical data and PROMs are col-
lected at visit 7 and 8. Detailed information about the
collected data during the patients’ visits is displayed in
Table 2 (SPIRIT figure).
Visit 1 (preoperative, informed consent)
After informed consent, the following data items will be
collected during visit 1: a.) demographic data; c.) baseline
data d.) previous abdominal surgeries; e.) medical history;
f.) HRQoL according to CAT EORTC QLQ-C30 [39, 40];
g.) PRO-CTCAE [13] of 12 core cancer-associated symp-
toms [14].
Visit 2 (surgery)
During surgery, the following parameters will be re-
corded: a.) duration of surgery; b.) estimated blood loss;
Table 1 Milestones and study time plan
1 Preparation of trial, Ethic votes, database set-
up
3 months
2 Initiation, training course for participants
(including preparation) (overlap with 1)
1 month
3 Recruitment period 2 months
5 Follow-up period 6 months per
patient
7 query management, database clearing 3 months
8 Report, publication 3 months
Total 18 months
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c.) intraoperative blood transfusion; d.) surgery per-
formed including completeness of macroscopic tumour
resection; e.) category of surgery (upper-GI, pancreatic,
hepatobiliary, colorectal, other); f.) degree of contamin-
ation according to the Centers for Disease Control and
Prevention (CDC) definition [41].
Visit 3 (postoperative day 3–5)
This visit is performed to document short-term clinical
outcome (complication rate). The following data items
need to be documented: a.) survival; b.) discharge; c.)
PRO-CTCAE symptoms; d.) reoperation(s); e.) complica-
tions according to Clavien-Dindo; f.) surgical site infec-
tions (SSI) including grading according to the CDC
classification [41]; g.) weight.
Visit 4 (postoperative day 6–8)
Visit 4 has an equivalent content to visit 3, with the ex-
ception of the PRO-CTCAE symptoms, which are NOT
documented during visit 4. If the patient is discharged
before day 6–8, visit 4 is omitted.
Visit 5 (postoperative day 10–14)
Visit 5 has an equivalent content to visit 3. If the patient
is discharged before day 10, visit 5 is omitted.
Visit 6 (postoperative day 30–35 or at discharge)
Visit 6 is performed once between postoperative day 30–
35 or at discharge if the patient leaves before day 30. The
following data items need to be documented: a.) survival;
b.) PRO-CTCAE symptoms; c.) CAT EORTC QLQ-C30;
d.) reoperation(s); e.) complication assessment according
to the Clavien-Dindo classification; f.) SSI assessment ac-
cording to the CDC classification; g.) weight.
Visit 6TEL (postoperative day 30–35)
Visit 6TEL is performed if the patient has been discharged
before postoperative day 30–35. If the patient is still in hos-
pital on day 30–35 visit 6TEL is omitted. The visit should be
conducted between day 30–35. This visit can be performed
in person (outpatient clinic) or, if the patient cannot be seen
in person, on the phone. The following data items have to
be collected: a.) survival; b.) PRO-CTCAE symptoms; c.)
CAT EORTC QLQ-C30; d.) reoperation(s); e.) (re-)hospital-
ization; f.) complication assessment according to the
Clavien-Dindo classification; g.) SSI assessment according
to the CDC classification; h.) details of postoperative onco-
logical treatment; i.) weight.
Visit 7/8 (postoperative month 3/6)
Visit 7 and 8 have equivalent contents. Visit 7 and 8 can
be performed in person (in person follow-up) or as a tele-
communication visit (e.g. phone). The following data
items need to be recorded: a.) survival; b.) PRO-CTCAE;
c.) CAT EORTC QLQ-C30; d.) weight; e.) reoperation(s);
f.) (re-)hospitalization; g.) oncologic treatment; h.) compli-
cation(s) according to the Clavien-Dindo classification.
Event Visit1-x (anytime between visit 1–8)
Event visits are optional, i.e. they do not have to be per-
formed but can be performed if necessary. The objective
is to document survival, complications and/or PROs
anytime during the study, i.e. between visit 1–8, if they
are not covered by the other visits. The following data
Fig. 1 Patient flow chart. CAT computer adaptive testing version, CTCAE Common Terminology Criteria of Adverse Events, EORTC European Organisation
for Research and Treatment of Cancer, HRQoL health-related quality of life, PRO patient-reported outcome, PROM patient reported outcome measure
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items should be collected: a.) date; b.) PRO-CTCAE; c.)
CAT EORTC QLQ-C30; d.) survival; e.) reoperation(s);
f.) hospitalization/readmission; g.) SSI assessment ac-
cording to the CDC classification; h.) complication as-
sessment according to the Clavien-Dindo classification;
i.) oncological treatment; j.) weight.
Risk-benefit assessment
As this is a non-interventional, observational study, no
beneficial treatment effect is to be expected. Accordingly,
no additional risk is expected for the individual partici-
pant. However, patients might benefit from more frequent
and more thorough postoperative clinical visits by the
local mini-teams. Furthermore, the study allows the pa-
tients to measure and feedback a number of PROMs
which is not available for non-participating patients. Dur-
ing digital PROM evaluation patients have the opportunity
to contact their local study team. Finally, the results of the
study could benefit future patients by integrating and im-
proving PROMs in the clinical treatment of cancer pa-
tients. Given the risk-benefit assessment no ancillary or
post-trial care or compensation to those who suffer harm
from the study is planned.
Ethical and legal aspects, informed consent
The PATRONUS study will be conducted in agreement
with the Declaration of Helsinki in its current version.
This study protocol has been written and the study will
be conducted and analysed in accordance with relevant
national and international rules and regulations includ-
ing international conference of harmonization good clin-
ical practice (ICH-GCP) guidelines.
All patients will be informed of the aims and conduct
of the study to allow an individual risk-benefit assess-
ment based on informed consent. It will be emphasised
that the participation is voluntary and that the patient is
allowed to refuse further participation in the study
whenever he/she wants to. In case of withdrawal from
the study the patient will be asked whether her/his pre-
viously collected data may be used for analysis or not. In
the latter case, all pseudonymised data entered in the
eCRF will be deleted.
Table 2 Adapted SPIRIT figure showing the visits and documented parameters of the PATRONUS study
Activity Visit 1
(screening,
consent)
Visit 2
(surgery)
Visit 3–6 (POD 3–5, 6–8, 10–14,
30–35 or at discharge)
Visit 6TEL (POD 30–35 if patient has
been discharged before)
Visit 7/8 (postoperative
month 3 and 6)
expenditure of time
per visit approx
20–25 min – 15 min 15 min 15 min
Inclusion/exclusion
criteria
X
Informed consent X
Demographics and
baseline data
X
Documentation of
PROMs:
a.) 12 symptoms
PRO-CTCAE*
b.) cancer-specific
HRQoL**
X X§ X X
Surgery X
Postoperative
morbidity***
X X
SSI$ X X
Length of hospital
stay
X X X
Reoperations X X X
(Re)admissions X X X
Overall survival X X X
* 12 symptoms as recommended by the National Cancer Institute: fatigue, insomnia, pain, anorexia, dyspnoea, cognitive problems, anxiety, nausea, depression,
neuropathy, constipation, diarrhoea assessed via PRO-CTCAE™
** according to the EORTC quality of life questionnaire C30
*** according to Clavien-Dindo
$ Documentation of SSI according to CDC [40, 41]
§ HRQoL once only on POD 30–35 or at discharge (Visit 6)
TEL Visit can be performed by telephone
SSI surgical site infection, CDC Centers of Disease Control and Prevention, POD postoperative day, OS overall survival, PROM patient-reported outcome measure,
CTCAE Common Terminology Criteria of Adverse Events, HRQoL health-related quality of life
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It is the responsibility of the investigator/medical stu-
dent to maintain patients’ confidentiality. During the
study, patients will be identified solely by means of their
individual identification code. Study specific documents
and patient data will be stored in accordance with local
data protection law/ ICH-GCP Guidelines at the local
trial sites and will be handled in strict confidence and in
line with the obligations of medical secrecy, the EU Gen-
eral Data Protection Regulation (Datenschutzgrundver-
ordnung), the Federal Data Protection Act
(Bundesdatenschutzgesetz) and the State Data Protection
Act (Landesdatenschutzgesetz). Participating patients’
data will be recorded in pseudonymised form.
The trial may be prematurely closed by the coordinat-
ing investigators in consultation with the responsible
statistician and the steering committee. Reasons that
may necessitate termination of the study include a.) it
appears that patients’ enrolment is unsatisfactory with
respect to quality and/or quantity or data recording is
severely inaccurate and/or incomplete; b.) External evi-
dence demanding a termination of the trial. The inde-
pendent ethics committee (IEC) must then be informed.
The results of the trial will be published in a
peer-reviewed journal under the authorship of CHIR-Net
SIGMA. All participating personel will be listed with their
specific contribution. Results will be distributed to the
public via www.sigma.university, www.facebook.com/sig
mastudynetwork and https://twitter.com/sigmastudies.
Data management
An electronic case report form (eCRF) will be used for
data collection. To assure a safe and secure environment
for data acquired, the RedCap™ system (www.project-
redcap.org) will be used for remote data entry [42]. Red-
Cap™ is validated and compliant with FDA 21 CRF part
11. Data transmission is encrypted with secure socket
layer (SSL) technology. The database server is located in
a secure data centre at the University of Heidelberg,
Germany and is protected by a firewall. The system pro-
vides an infrastructure to support user roles and rights.
Only authorised users are able to enter or edit data, the
access is restricted to data of the patients in the respect-
ive centre. All changes to data are logged with a comput-
erized timestamp in an audit trail. All clinical data will
be pseudonymized. Backups are conducted regularly.
All protocol-required information collected during the
study will be entered by an authorised member of the
mini-team in the eCRF. For HRQoL and PRO-CTCAE
results, patients may directly enter the data in the eCRF.
Any outstanding entries must be completed immediately
after the final examination. An explanation should be
given for all missing data. The completed eCRF must be
reviewed and signed by an authorised member of the
mini-team.
In order to guarantee quality, validity and plausibility
of data, a data validation plan is implemented which uses
real-time edit-checks and validating programs, which
will generate queries. The investigator, medical student
or the designated representatives are obliged to clarify
the edit-checks and queries.
All data will be integrated in a statistical analysis sys-
tem. The data access is restricted to the data manager
and the biometricians responsible for the trial. The data
will be managed and analysed in accordance with the ap-
propriate Standard Operating Procedures valid in the In-
stitute of Medical Biometry and Informatics at the
University of Heidelberg.
A study-specific data validation plan has been established
ensuring that implausibility of data, missing data and imbal-
ances between centers, e.g. reporting of postoperative com-
plications are revealed. In this case, queries will be sent to
the centres and need to be resolved by the mini-teams. In
the PATRONUS study only a limited on-site monitoring
will be performed. An external monitor will check, whether
signed informed-consent forms are available for all patients.
Statistical procedures
Since this is an exploratory study, all analyses will be de-
scriptive and p-values < 0.05 will be referred to as statistically
significant in descriptive sense. The patient characteristics
and outcomes will be described for the whole cohort and
for the different subgroups divided according to tumour en-
tity with appropriate descriptive statistics (mean, standard
deviation, median, interquartile range, minimum, maximum
in case of continuous data and scores, or absolute and rela-
tive frequencies in case of categorical data).
To analyse the association between perioperative com-
plications (Clavien-Dindo grading) and the set of 12
PRO-CTCAE symptoms as well as the subscales of CAT
EORTC QLQ-C30 in the short- and long-term, Spear-
man’s rank-correlation coefficients (Spearman’s rho) will
be calculated and analysis of variance will be performed.
For the description of the absolute values of the CAT
EORTC QLQ-C30 as well as the set of 12 cancer-specific
symptoms measured via the PRO-CTCAE appropriate de-
scriptive measures will be reported.
Possible overlapping between the two PROMs (PRO-CT-
CAE and CAT EORTC QLQ-C30) will be analysed calcu-
lating Spearman’s rhos between the respective scales.
The rates of missing PRO data, clinical data and the
rate of included patients compared to screened patients
will be calculated and reported with adequate descrip-
tive measures. The number of participating trial sites
including patients compared to initiated trial sites and
the rate of included patients in comparison to screened
patients per trial site will be calculated, as well. The
achievement of the respective goal rates will be evalu-
ated by binomial tests.
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Further analysis includes correlations between ASA
score, comorbidities, neoadjuvant therapy, socio-economic
factors, smoking, alcohol consumption and other baseline
factors and subscales of the two PROMs and complications.
Survival analysis includes Kaplan-Meier graphs and
log-rank-tests between different tumour entities. Cox
regression analysis will be performed to evaluate possible
relationships between survival and different baseline
covariates.
Wherever appropriate, graphics will be created to il-
lustrate the data and findings. Details of the statistical
analysis will be described in the statistical analysis plan,
which will be written prior to the database closure. For
the statistical analysis, IBM SPSS Statistics Version 24
(or higher) and SAS (SAS Institute, Cary, NC, USA) ver-
sion 9.4 (or higher) will be used. No interim analysis is
planned.
Sample size calculation
Since this is an exploratory cohort study, no formal sam-
ple size calculation was done. Assuming 30 clinics to
participate and a recruiting rate of about evaluable 30
patients per centre, we assume to have the data of about
900 patients to evaluate. This sample size is big enough
to give answers with a good precision overall and in spe-
cific subgroups such as different cancer entities.
Missing values
Due to the nature of the study (observational cohort
study) no imputation of missing values will be provided.
Appearance and frequency of missing data is examined
in line with the objectives of the study.
Discussion
Given the potential advantages of PROMs in clinical tri-
als [8, 43] astonishingly little focus has been put on
PROMs in surgical oncology. Here PROMs are fre-
quently analysed inadequately (e.g. not addressing miss-
ing data) and are rarely the main focus of investigation.
Consequently, very little is known about the relationship
of clinical endpoints including postoperative surgical
complications and PROMs in surgical oncology. In
addition, previous studies investigating the relationship
between PROMs and complications in abdominal cancer
surgery have frequently used a cross-sectional design
with inadequate validity [17–19] and results are thus
questionable [20]. Moreover, most studies have focused on
colorectal cancer surgery only, have reported conflicting re-
sults and lacked standardized complication measurements.
Similar to our planned PATRONUS study Bosma et al.
have used a prospective observational design to analyse
patients undergoing colorectal surgery and found an asso-
ciation between the severity of complications (measured
via Clavien-Dindo) and HRQoL within the first 6 weeks,
but not after 12 months [22]. However, this study had a
single-centre design, used the short version of the WHO
HRQoL assessment instrument [44], which covers no
cancer-specific symptoms and is a generic, i.e. not
cancer-specific HRQoL tool. In contrast, Di Cristofaro et al.
reported no significant relationship between complications
and global HRQoL (EORTC QLQ-C30, -CR29) in their
prospective trial of 166 patients in 3 centres undergoing
colorectal cancer surgery [21]. The randomised-controlled
CLASSIC trial (laparoscopic vs. open resection for colorec-
tal cancer) reported yet another result by prospectively ana-
lysing the HRQoL (generic EQ5D and cancer-specific
EORTC QLQ-C30/CR38) in 614 randomised patients [23].
In contrast to the previous trials, significant long-term dif-
ferences in QoL between patients with and without compli-
cations were found for Physical and Social Function, Role
Functioning, and Body Image on EORTC QLQ-C30/
QLQ-CR38 analysis and Mobility, Self-care, and Pain/Dis-
comfort on EQ5D analysis. In line with these findings An-
thony et al. reported an association with postoperative
complications (no standardised evaluation) and postopera-
tive HRQoL at 12 months using the Functional Assessment
of Cancer Therapy (FACT-C) tool in 63 patients undergo-
ing open colorectal cancer surgery [24]. For other types of
abdominal cancer entities, results are even rarer including
the study by Heerkens et al. who found no statistically sig-
nificant and clinically relevant differences in HRQoL (using
the EORTC QLQ-C30, -PAN26 and RAND26 question-
naire) between patients with severe compared to no/mild
complications following pancreatic surgery in their single
centre study [25] and Rutegard et al. who has analysed the
Swedish national cancer registry for patients undergoing
oesophagectomy for cancer and reported significantly im-
paired HRQoL (EORTC QLQ-C30 and -OES18) at
6 months in patients who had experienced technical surgi-
cal complications [26].
In summary, studies investigating the relationship be-
tween postoperative complications and PROMs are
sparse and many studies exhibit severe methodological
shortcomings. In addition, studies have used a multitude
of different PROMs impeding direct comparison of re-
sults. In the meantime, clear recommendations exist for
oncological trials to focus on two PROMs, namely
HRQoL (either generic, cancer-specific or cancer-type
specific) and cancer specific symptoms [8, 14]. For the
latter the NCI has recently published recommendations
which cancer-specific symptoms should be evaluated in
all cancer patients (core set of 12 symptoms) [14], but
has not specified the tools that should be applied to
measure these symptoms. The EORTC QLQ-C30 has
become one of the most widely used tools to measure
cancer-specific HRQoL over the last decades [39] and
recently a computerised adaptive version has been devel-
oped but not yet tested in surgical oncology. Similarly,
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the PRO-CTCAE symptoms score might be a fitting
candidate to assess the proposed core set of cancer
symptoms but again its evaluation in surgical oncol-
ogy is pending. Therefore, a prospective multicentre
study using an accepted complication measurement
(Clavien-Dindo classification) and the two new PROMs
as planned in our PATRONUS study seems urgently
warranted.
Furthermore, a direct comparison of the two tools in
overlapping domains (cancer-symptoms) is pending
given their so far limited application in oncology. Again
this issue will be studied in our study.
Although PROMs have numerous potential advantages
their true benefit has been limited and PROMs have
‘[…] rarely been informative from a licensure perspec-
tive’ [8]. The reasons for this are methodological aspects
of PROMs that are frequently not adequately addressed
in clinical trials including a.) inadequate PROM develop-
ment [43]; b.) inadequate psychometric reliability, valid-
ity and responsiveness [43, 45]; c.) lack of an a priori
specification of the expected effect size, PRO domain
under investigation and sample size calculation [8] and
d.) missing data, adding to attrition bias and necessitat-
ing the a priori specification of imputation methods [46].
While the first two aspects are not a concern for the two
PROMs selected for our study, sample size calculation
and missing data might be a concern, especially in surgi-
cal oncology with patients experiencing complications
being less likely able to fill out PROMs. PATRONUS will
create a sound database for sample size calculation for
future clinical trials and will also offer a good estimate
of the rate of missing data which can be expected in the
context of surgical oncology and digital PROM
assessment.
An important aspect of the PATRONUS study is the
design and conduct by medical students. PATRONUS al-
lows medical students to interact with concepts and
methods of clinical research thereby potentially inspiring
their orientation towards academic careers and work as
clinician scientists [27, 28]. Although the conduct of
multicentre clinical observational studies is relatively
new, previous examples in the UK have shown the feasi-
bility of this concept [33]. However, PATRONUS will
add some important aspects compared to previous stud-
ies as patients will need to undergo written informed
consent, PRO evaluation is performed, the follow-up is
significantly longer and the study design more complex.
The limitations of the PATRONUS study are numerous.
First, it is a single-arm observational study and therefore
cannot elucidate a causal relationship. It will, however,
serve to generate hypotheses for future clinical research.
Second, data quality might be a concern. It is unclear if
the assessment of postoperative complications performed
by medical students is comparable to the assessment of
trained doctors or study nurses. However, the SIGMA
study group has implemented a number of measures to en-
sure high quality data assessment including a data valid-
ation plan (see methods section), centralized monitoring
and training of participating study personnel in the SIGMA
clinical trials curriculum prior to study initiation. Briefly,
this curriculum includes a.) an obligatory e-learning session
on the Clavien-Dindo classification; b.) lectures on the ba-
sics of evidence based medicine, levels of evidence, study
types, statistical analysis plan, ethics, laws and regulatory
obligations, Good Clinical Practice, and basics of data
management; c.) workshops on acquiring informed
consent from patients with actors and video-feedback,
on how to improve patient recruitment, RedCap data-
base training and bedside-teaching with Clavien-Dindo
assessment. Within the PATRONUS study, only limited
onsite monitoring will be done. An external monitor
will check whether signed informed consent forms are
available from all patients. However, no source data
verification will be implemented. This is in contrast to
the more enhanced data verification plans of other re-
lated study projects (e.g. EuroSurg Imagine trial) [47].
Third, as pointed out above the rate of SSIs according
to CDC will be assessed as a secondary outcome param-
eter in our study. It is known from the analysis of RCTs,
that there is an underreporting of SSIs if assessed as sec-
ondary endpoints compared to the assessment as primary
endpoint [48]. Nonetheless, as SSI are among the most
frequent postoperative complications assessment seems
necessary both from an education and clinical perspective.
Fourth, as this is the first student-led study in
Germany and of the CHIR-Net SIGMA group, feasibility
and recruitment is unclear. Finally, many aspects of the
concept of student-led clinical research warrant further
evaluation.
Trial status
Ethical approval was granted by the independent ethics
committee of the Medical Faculty of the University of Hei-
delberg on 11th September 2017 (version 1.1; reference
S-466/2017) and patient recruitment started in
February 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOCX 62 kb)
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